Storys aus Denmark

28.09.2018 – 10:02
Novo Nordisk
International Diabetes Federation (IDF) Global Survey Reveals 2 in 3 People With Type 2 Diabetes Have Cardiovascular Disease Risk Factors and/or Have Experienced a Cardiovascular Event
Bagsværd, Denmark (ots/PRNewswire) - - Cardiovascular disease (CVD) is the leading cause of disability and death in people with type 2 diabetes[1] - Despite the high incidence, 1 in 4 people with type 2 diabetes have never discussed, or cannot recall discussing, CVD risk factors with a doctor[2] - First-ever global ...
mehr
23.06.2018 – 14:06
Novo Nordisk
Significant Blood Sugar Improvement With Xultophy® Compared to Insulin Glargine U-100 When Used as Add-On to Oral Diabetes Medications
Bagsværd, Denmark (ots/PRNewswire) - Oral Presentation #127-OR Adults with type 2 diabetes treated with Xultophy® (insulin degludec and liraglutide injection) also experienced no change in body weight, lower rates of hypoglycaemia and a lower insulin dose at 26 weeks Xultophy® (insulin degludec and liraglutide ...
mehr
05.04.2018 – 15:54
Enghouse Systems Limited
Enghouse Systems Acquires Mobilethink A/S
Markham, Ontario and Aarhus, Denmark (ots/PRNewswire) - Acquisition expands Enghouse Networks product portfolio Enghouse Systems Limited (TSX: ENGH) announced today it has acquired Mobilethink A/S of Aarhus, Denmark. Mobilethink A/S is a software business specializing in device management solutions, with two leading brands in the mobile B2B sector. The principal brand, trademarked Mobilethink, is a comprehensive mobile ...
mehr
01.02.2018 – 09:31
Novo Nordisk
Semaglutide Demonstrated Significant Reductions in Blood Sugar and Weight Compared with Dulaglutide; Results Published in The Lancet Diabetes & Endocrinology
Bagsværd, Denmark (ots/PRNewswire) - Results from the SUSTAIN 7 trial, which investigated the efficacy and safety of 0.5 mg semaglutide compared with 0.75 mg dulaglutide and 1.0 mg semaglutide compared with 1.5 mg dulaglutide, when added to metformin, have been published in The Lancet Diabetes & Endocrinology.[1] ...
mehr
19.12.2017 – 11:01
Enghouse Systems Limited
Enghouse Systems Acquires SimaTech
Markham, Ontario and Brondby, Denmark (ots/PRNewswire) - Acquisition Expands Product Portfolio For The Public Safety & Utilities Sectors Enghouse Systems Limited (TSX: ENGH) announced today it has acquired SimaTech A/S of Denmark. Headquartered in Brondby (near Copenhagen), SimaTech provides products and solutions for the law enforcement, fire and rescue, control room and utilities sectors. SimaTech's turn-by-turn navigation, fleet, asset, and incident management systems ...
mehr
18.12.2017 – 20:51
Canopy Growth Corporation
Cannabis Production in the European Union - Spectrum Denmark Granted Production Licence
Odense, Denmark, and Smiths Falls, Ontario (ots/PRNewswire) - Further to a December 5th press release announcing plans to establish a 40,000 m2 facility in the Danish city of Odense, Spectrum Cannabis Denmark has been issued a cannabis production licence by Laegemiddelstyrelsen, Denmark's Medicines Agency. Danish Health Minister, Ellen Trane Nørbye, announced the news ...
mehr

11.12.2017 – 09:02
Novo Nordisk
Xultophy® Significantly Reduces Blood Sugar Levels, Body Weight and Risk of Hypoglycaemia for People With Type 2 Diabetes in Real-World Setting
Bagsværd, Denmark (ots/PRNewswire) - - Results published in Diabetes, Obesity and Metabolism Newly published data from real-world European clinical practice has shown that Xultophy® (insulin degludec/liraglutide) significantly reduced blood sugar levels in people with type 2 diabetes after six months.[1] The study ...
mehr
05.12.2017 – 10:02
Novo Nordisk
Switching to Tresiba® Benefits People with Diabetes Irrespective of Blood Sugar Levels in a Real-world Setting
Bagsværd, Denmark (ots/PRNewswire) - - Switching to Tresiba® reduced the rate of hypoglycaemia by 67% in people with controlled blood sugar levels - In people with diabetes whose blood sugar was too high, switching to Tresiba® significantly improved blood sugar levels Switching to Tresiba® from another basal ...
mehr
04.12.2017 – 07:56
Novo Nordisk
Xultophy® Offers Greater Blood Sugar and Body Weight Reductions in People With Type 2 Diabetes, Compared to IGlarLixi
Copenhagen, Denmark (ots/PRNewswire) - New findings from an indirect comparison between Xultophy® and IGlarLixi published in the Journal of Medical Economics show that treatment with Xultophy® (insulin degludec/liraglutide) provides statistically significant greater reductions in blood sugar levels and body weight ...
mehr
27.07.2017 – 15:04
LEO Pharma
LEO Pharma Ranks Second in Global Clinical Trials Transparency Audit
Ballerup, Denmark and Hurley, England (ots/PRNewswire) - New top 50 list ranks LEO Pharma in second position, leading the global pharma industry in commitments to increase access to clinical trials information (Logo: http://photos.prnewswire.com/prnh/20130221/595427 ) The AllTrials audit on clinical trial transparency findings has been published ranking LEO Pharma as leaders in the industry. LEO Pharma is ranked at number ...
mehr
20.07.2017 – 09:01
LEO Pharma
LEO Pharma Receives Marketing Authorisation for Kyntheum® (Brodalumab), a New Biologic for the Treatment of Moderate-to-Severe Plaque Psoriasis in the European Union
Ballerup, Denmark (ots/PRNewswire) - LEO Pharma today announced that the European Commission has granted marketing authorisation for Kyntheum® (brodalumab), a new biologic for the treatment of moderate-to-severe plaque psoriasis in adults within the European Union who are candidates for systemic therapy.[1] ...
mehr
07.07.2017 – 11:01
ALK
ALK - Five-year GRAZAX® Asthma Prevention (GAP) Trial Reveals Benefits of Early Treatment Intervention in Children
Hørsholm, Denmark (ots/PRNewswire) - - The disease modifying property of GRAZAX® (SQ® grass SLIT-tablet) resulted in long-term effect on allergic rhinoconjunctivitis (ARC) and prevented asthma symptoms, even two years after end of treatment in children with grass pollen ARC and no existing signs or symptoms of ...
mehr

03.07.2017 – 09:02
Novo Nordisk
Novo Nordisk to Present 35 Abstracts at the International Society on Thrombosis and Haemostasis Congress
Bagsvaerd, Denmark (ots/PRNewswire) - Novo Nordisk announced today that data from 35 abstracts will be presented at the upcoming International Society on Thrombosis and Haemostasis (http://www.isth.org/) (ISTH) congress from 8-13 July, in Germany. This data will be featured across posters, abstracts and oral ...
mehr
30.06.2017 – 12:20
ALK
ALK: Five-year GRAZAX® Asthma Prevention (GAP) Trial Reveals Benefits of Early Treatment Intervention in Children
Hørsholm, Denmark (ots/PRNewswire) - - The disease modifying property of GRAZAX® (SQ® grass SLIT-tablet) resulted in long-term effect on allergic rhinoconjunctivitis (ARC) and prevented asthma symptoms, even two years after end of treatment in children with grass pollen ARC and no existing signs or symptoms of ...
mehr
20.06.2017 – 11:02
ALK
ALK Symposium Reveals Early Treatment is Critical for Respiratory Allergic Disease in Children and Adolescents
Hørsholm, Denmark (ots/PRNewswire) - - Allergic rhinitis has a major impact on children's quality of life - Children with allergic rhinitis have an increased risk of developing asthma - Early treatment may prevent asthma symptoms In a symposium sponsored by ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF), leading ...
mehr
15.06.2017 – 07:01
LEO Pharma
LEO Pharma Starts Phase 3 Clinical Study for Tralokinumab in Atopic Dermatitis
Ballerup, Denmark (ots/PRNewswire) - LEO Pharma today announced that the first patients have been dosed in a phase 3 clinical study of tralokinumab. Tralokinumab is an investigational human monoclonal antibody that specifically targets the cytokine IL-13[1], which plays an important role in the development of moderate-to-severe atopic dermatitis[2]. Tralokinumab is not ...
mehr
13.06.2017 – 03:31
Novo Nordisk
New LEADER Analysis Shows Victoza® Reduces Cardiovascular Risk in People With Type 2 Diabetes Regardless of Severe Hypoglycaemia Events
Bagsværd, Denmark (ots/PRNewswire) - Findings from a post hoc analysis of the LEADER cardiovascular (CV) outcomes trial showed that treatment with Victoza® (liraglutide) resulted in similar reductions in the risk of major cardiovascular events in people with type 2 diabetes at high CV risk, regardless of whether ...
mehr
10.06.2017 – 19:02
Novo Nordisk
Switching to Tresiba® Provides Significant Reductions in Blood Glucose and Lower Rates of Hypoglycaemia in a Real-world Setting
Bagsværd, Denmark (ots/PRNewswire) - Poster Presentations #999-P, #1010-P, #1014-P Findings from the real-world study, EU-TREAT (EUropean TREsiba AudiT), were presented today at the American Diabetes Association's 77th Scientific Sessions (ADA) in San Diego, US. The study showed that people with type 1 diabetes and ...
mehr

22.05.2017 – 08:01
LEO Pharma
Brodalumab, a Novel Biologic for People with Moderate-to-Severe Psoriasis, Receives Positive Opinion from European CHMP
Ballerup, Denmark (ots/PRNewswire) - Opinion from CHMP: "On 18 May 2017, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product [brodalumab], intended for the treatment of psoriasis[...]The benefits with ...
mehr
19.05.2017 – 18:06
LEO Pharma
Brodalumab, a Novel Biologic for People with Moderate-to-Severe Psoriasis, Receives Positive Opinion from European CHMP
Ballerup, Denmark (ots/PRNewswire) - Opinion from CHMP: "On 18 May 2017, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product [brodalumab], intended for the treatment of psoriasis[...]The benefits with ...
mehr
27.03.2017 – 09:03
Novo Nordisk
Fiasp®, a new, ultra-fast acting mealtime insulin is available for the treatment of diabetes in adults
Bagsværd, Denmark (ots/PRNewswire) - Canada first country to launch Fiasp® This material is intended for global medical media only. For journalistic assessment and preparation before publication. Today, Novo Nordisk announced that Fiasp®, a new, fast-acting mealtime insulin for the treatment of diabetes in ...
mehr
03.03.2017 – 16:01
LEO Pharma
LEO Pharma Announces Positive Results From Phase 2b Clinical Study for Tralokinumab in Atopic Dermatitis
Ballerup, Denmark and Orlando, Florida (ots/PRNewswire) - LEO Pharma today announced positive results from a Phase 2b dose-ranging efficacy and safety study of tralokinumab in adult patients with moderate to severe atopic dermatitis (AD), a serious and chronic form of eczema. Tralokinumab is an investigational ...
mehr
27.02.2017 – 14:49
ALK
ALK's ACARIZAX® Data Results in Significant Change to the GINA Asthma Management Strategy: Sublingual Allergy Immunotherapy (SLIT) Recommended as a Treatment Option in Patients With House Dust Mite Allergic Asthma
Hørsholm, Denmark (ots/PRNewswire) - ALK (ALKB: DC / OMX: ALK B / AKABY / AKBLF) today announced that for the first time, allergy immunotherapy is now recommended as a treatment option in the Global Initiative for Asthma (GINA) report: Global Strategy for Asthma Management and Prevention. This global strategy is a ...
mehr
07.12.2016 – 08:01
Saxo Bank (Switzerland) SA
Saxo Bank's 10 Outrageous Predictions for 2017
Copenhagen, Denmark (ots/PRNewswire) - Will this be the year when China exceeds growth expectations, Brexit turns into Bremain, the Mexican peso soars and Italian banks turn out to the best performing equity asset class? Saxo Bank, the online multi-asset trading and investment specialist, has today released its annual set of 'Outrageous Predictions' for the year ahead. Continuing in the tradition of making a selection of ...
mehr

03.12.2016 – 18:01
Novo Nordisk
NovoSeven® Resolved 96.5% of Bleeds When Initiated Within One Hour After Bleed Onset in People With Haemophilia A or B With Inhibitors
Bagsværd, Denmark (ots/PRNewswire) - This material is intended for global medical media only. For journalistic assessment and preparation before publication. Novo Nordisk today announced that NovoSeven® (rFVIIa), a portable room temperature stable recombinant activated factor VIIa, resolved 96.5% of bleeds when ...
mehr
02.12.2016 – 09:02
Novo Nordisk
Xultophy® Demonstrates Similar Glucose Control with Reduced Risk of Hypoglycaemia and a Superior Weight Profile Compared to Basal-Bolus Therapy
Bagsværd, Denmark (ots/PRNewswire) - This material is intended for global medical media only. For journalistic assessment and preparation before publication. Novo Nordisk today announced new phase 3b trial (DUAL VII) results with Xultophy® (IDegLira). Xultophy® is a once-daily, single injection fixed combination ...
mehr
12.11.2016 – 09:01
Novo Nordisk
Tresiba® Demonstrated Lower Day-to-Day and Within-Day Variability in Glucose-Lowering Effect Compared With Insulin Glargine U300
Bagsværd, Denmark (ots/PRNewswire) - This material is intended for global medical media only. For journalistic assessment and preparation before publication. Results from a study comparing the pharmacodynamics of Tresiba® (insulin degludec) with insulin glargine U300 in people with type 1 diabetes were presented ...
mehr
16.09.2016 – 15:53
Novo Nordisk
NovoRapid® receives positive CHMP opinion for extended use in children as young as one year old
Bagsværd, Denmark (ots/PRNewswire) - This material is intended for global medical media only. For journalistic assessment and preparation before publication. Novo Nordisk today announced that the Committee for Medicinal Products for Human Use, CHMP, has adopted a positive opinion to extend the use of NovoRapid® (insulin aspart) in the European Union for children with ...
mehr
07.09.2016 – 08:03
UNOPS
UN Publication Examines How Procurement Can Address the World's Most Pressing Challenges
Copenhagen, Denmark (ots/PRNewswire) - Around the world, innovative approaches are being developed to support humanitarian aid and drive sustainable development. From using drones to save lives and spur development, to the private sector fighting human rights abuses in other countries: these are just a few of the ground-breaking ideas in a new publication by UNOPS. ...
mehr
11.07.2016 – 18:01
Novo Nordisk
Novo Nordisk to Present 28 Abstracts at the World Federation of Hemophilia Congress
Bagsværd, Denmark (ots/PRNewswire) - This material is intended for global medical media only. For journalistic assessment and preparation before publication. Novo Nordisk announced today that data from 28 abstracts will be shared at the upcoming World Federation of Hemophilia World Congress (WFH) in Orlando, Florida, from 24-28 July. The WFH Congress is the largest ...
mehr

Vorherige123456Nächste